Table 2:
Treatment and tumour characteristics
| Characteristic | Open approach (n = 203) | VATS approach (n = 69) | P-value |
|---|---|---|---|
| Induction chemotherapy (n, %) | 0.47 | ||
| Platinum doublet therapy | 164 (81) | 57 (84) | |
| Platinum only | 1 (0.5) | 0 (0) | |
| Epidermal growth factor receptor inhibitor | 1 (0.5) | 1 (1) | |
| Taxane only | 5 (2) | 0 (0) | |
| Other | 6 (3) | 0 (0) | |
| Unknown | 26 (13) | 10 (15) | |
| Pathological T status (n, %) | 0.017 | ||
| T0 | 59 (29) | 15 (22) | |
| T1a | 40 (20) | 10 (14) | |
| T1b | 11 (5) | 12 (17) | |
| T2a | 34 (17) | 18 (26) | |
| T2b | 16 (8) | 6 (9) | |
| T3 | 39 (19) | 7 (10) | |
| T4 | 4 (2) | 1 (1) | |
| Pathological N status (n, %) | 0.23 | ||
| N0 | 146 (72) | 42 (61) | |
| N1 | 23 (11) | 11 (16) | |
| N2 | 34 (17) | 16 (23) | |
| Pathological M status (n, %) | 0.74 | ||
| M0 | 188 (93) | 65 (94) | |
| M1 | 14 (7) | 4 (6) | |
| Histology (n, %) | 0.012 | ||
| Adenocarcinoma | 75 (37) | 35 (51) | |
| Adenosquamous | 2 (1) | 2 (3) | |
| Squamous | 61 (30) | 24 (35) | |
| Large cell | 12 (6) | 3 (4) | |
| Non-small cell, not otherwise specified | 53 (26) | 5 (7) | |
| Complete pathological response (n, %) | 52 (26) | 15 (22) | 0.52 |
| Preinduction therapy tumour sizea (cm), mean ± SD | 4.8 ± 2.5 | 4.2 ± 2.4 | 0.22 |
| Postinduction therapy tumour size (cm), mean ± SD | 2.7 ± 2.8 | 2.8 ± 2.2 | 0.42 |
| Down-staged from PN2 to PN0b (n, %) | 54 (59) | 20 (48) | 0.21 |
| Down-staged from PN2 to PN1 or PN0b (n, %) | 64 (70) | 28 (67) | 0.67 |
| Overall down-stagec (n, %) | 121 (61) | 36 (58) | 0.67 |
FEV1: forced expiratory volume in 1 s; VATS: video-assisted thoracoscopic surgery; SD: standard deviation.
aData only available for 169 of 272 patients (open n = 124, VATS n = 45).
bDenominator used is the number of patients who had N2 disease in the open (n = 91) and VATS (n = 42) groups.
cData only available for 260 of 272 patients (open n = 198, VATS n = 62).